Type I interferon in HIV treatment: from antiviral drug to therapeutic target

Type I interferons (IFNs) are soluble molecules that exert potent antiviral activity and are currently used for the treatment of a panel of viral infections. In the case of HIV, the use of type I IFN has had limited success, and has almost been abandoned. During the last decade, a series of studies has highlighted how HIV infection may cause overactivation of type I IFN production, which contributes to the exhaustion of the immune system and to disease progression. This review describes the transition from the proposed use of type I IFN as antiviral drugs in HIV infection, to the idea that blocking their activity or production may provide an immunologic benefit of much greater importance than their antiviral activity.

KEYWORDS: anti-IFN-α antibodies (MEDI-545) - chloroquine/hydroxychloroquine - CpG oligodeoxynucleotides - HIV/AIDS - IFN-α/β - imiquimod/resiquimod - immunoregulatory sequences - plasmacytoid dendritic cells - soluble CD4-Ig - Toll-like receptors

The term ‘interferon’ was coined by Alick Isaacs and Jean Lindenmann in 1957 to describe the soluble factor responsible for interfering with the growth of influenza virus in vitro [1]. Different types of interferons (IFNs) have been identified and, with the exception of IFN-γ (type II IFN), are referred to as type I IFNs [2]. IFN-α (which comprises at least 22 glycoproteins produced by post-translational modification of 13 gene products), IFN-β, -ε, -κ, -oα and -o are the six species of type I IFN found in humans. In this review, the term ‘type I IFN’ will be used to describe IFN-α and IFN-β, the best characterized of this family of soluble molecules. The identification of the cellular sources of type I IFN, their pathways of induction and mechanisms of antiviral activity provided a number of potential molecular targets for therapeutic approaches.

The panel of genes expressed by the target cells upon engagement of the receptor for type I IFN (IFNAR) contribute to generate an intracellular environment that antagonizes viral replication [3,4]. 2–5-oligoadenylate synthetase and RNase L inhibit viral replication by degrading viral RNA [5]. The dsRNA-activated kinase PKR contributes to inhibit protein synthesis and activates NF-kB, favoring apoptosis of the target cells [6–10]. In addition, type I IFN play an important role in the development of T-cell-mediated antigen-specific immune responses by stimulating antigen presentation [11–13] and polarizing CD4 T-helper cells toward a Th1 response, which is efficient against viral infection [14,15].

There are two major pathways that result in the induction of type I IFN during viral infections. Retinoic acid-inducible gene-I-like receptors are cytoplasmic sensors that can recognize viral dsRNA in infected cells [16–18]. Toll-like receptor (TLR)-3, -7 and -9 are located in the endosomal compartment of specialized cells and recognize dsDNA, ssRNA and unmethylated CpG-rich DNA, respectively. These nucleic acids are common constituents of the genome of most viruses, which can be engulfed by endocytotic cells [16–18]. In particular, plasmacytoid dendritic cells (pDC) express both TLR-7 and -9 and are specialized in the recognition of viruses and in the production of very large amounts of type I IFN during innate immune responses [18,19]. Myeloid DC express TLR-3 and can also produce type I IFN [18].

Type I IFN responses can also be activated by stimuli that are not directly associated to viral components. For example, host-derived nucleic acids, derived from necrotic or apoptotic cells, can be engulfed by endocytotic cells and induce type I IFN production by TLR-dependent or -independent mechanisms [18,20,21].
**Type I IFN responses to HIV**

Similar to other viruses, HIV type 1 is recognized by the molecular sensors that activate innate immune pathways resulting in type I IFN production. The ability of type I IFN to inhibit HIV replication and the possibility to manipulate pDC responses have been a fertile ground for supporting potential therapeutic approaches aimed at taking advantage of this natural antiviral system. However, whilst therapies based on the antiviral activity of type I IFN proved to be efficacious in the treatment of other viral infections, their impact on the course of HIV disease has been minimal. Novel approaches are now being considered in light of the improved understanding of HIV pathogenesis. In particular, consideration is being given to the possibility that pDC and type I IFN may contribute to sustaining the status of chronic activation, which eventually results in the dismay of the immune system [22]. Inhibiting pDC activation and type I IFN production or signaling may therefore represent a new avenue for therapeutic approaches.

**Anti-HIV activity of type I IFN**

Since the first reports on the inhibitory effect of type I IFN on HIV replication, the obvious suggestion was made that such molecules could be used as therapeutic agents to control the infection [23]. Obstruction of HIV replication by type I IFN appears to occur at different stages of the viral cycle, with effects which may be specific for certain cell types [24]. Thus, the general antiproliferative and proapoptotic effect of type I IFN are only partially responsible for their anti-HIV activity. Of particular interest is the fact that monocytes/macrophages respond to type I IFN by upregulating and activating the apolipoprotein B mRNA-editing enzyme-catalytic polypeptide-like 3G (APOBEC3G), an intracellular enzyme that exerts potent antiretroviral activity [25]. APOBEC3G blocks HIV replication prior to integration of the proviral DNA into the target cell's genome [26], but its induction by type I IFN is not observed in CD4 T-cell lines [27]. The cell-specific induction pattern of APOBEC3G may partially explain why type I IFN primarily inhibits the assembly and release of HIV in chronically-infected CD4 T cells [24,28], whilst reducing the relative levels of viral RNA and integrated provirus in macrophages [24,29,30]. Recent evidence also suggest that type I IFN may exert anti-HIV activity through inducing tetherin, a molecule which impedes virus release from the cell surface and is antagonized by the HIV accessory protein Vpu [31,32]. The anti-HIV activity of type I IFN has also been confirmed in vivo in the artificial system of SCID mice transplanted with human cell lines or primary leukocytes [33].

**Type I IFN production during HIV infection**

HIV is a strong activator of pDC and potent inducer of type I IFN production in vitro, yet studies on type I IFN responses in HIV-infected patients have given apparently contrasting results on whether the type I IFN system is hypo- or hyperfunctional during chronic infection (reviewed in [34]). The interaction of HIV with CD4 expressed on pDC is required to allow its endocytosis and subsequent presentation of the viral nucleic acid to endosomal TLR-7 and -9, essential for pDC activation [35]. The peculiar ability of HIV to interact with CD4, combined with the rapid endocytosis of CD4 by pDC, lead to the suggestion that HIV may provide a particularly strong and protracted trigger for pDC [22]. Recognition of HIV RNA by TLR-7 is probably the main route of HIV-induced pDC activation [35,36], but a role for TLR-9 cannot be excluded.

pDC from HIV-infected patients are refractory to in vitro re-stimulation with TLR-7 and -9 ligands or with HIV itself, and the frequency of circulating pDC is reduced in peripheral blood during HIV infection [34]. The dynamics of circulating pDC have been described to follow the changes observed in CD4 count during HIV infection. Thus, circulating pDC decrease during primary HIV infection, and this reduction is partially prevented by early HAART [37]. Efficient HAART treatment also recovers the levels of circulating pDC and their responsiveness to TLR stimulation in chronically HIV-infected patients, but not in patients in whom the CD4 count restoration is impaired [38]. Although these observations suggest an impairment of pDC functionality and type I IFN responses during HIV infection, a number of recent reports outlined how the reduction and apparent hyporesponsiveness of circulating pDC are both consequences of chronic HIV-induced hyperactivation. Plasma levels of type I IFN were described to increase rapidly in macaques upon simian immunodeficiency virus (SIV) infection [39,40]. Abel and colleagues observed that the induction of type I IFN responses occurred early during acute infection and persisted throughout the
course of disease [39]. Expression of type I IFN and IFN-inducible genes was observed in different lymphoid tissues, and associated with high tissue SIV- or HIV-1 RNA rather than control of viral replication [39]. The chronic triggering of pDC may lead to their relocation to lymphoid tissues and to the induction of an apparent refractory status induced through negative feedback [41,42]. These findings reconcile with earlier observations that the levels of type I IFN and type I IFN-regulated genes, including those associated with apoptotic pathways, are increased in peripheral leukocytes and lymphoid tissues from HIV-infected patients [43–45]. Therefore, during HIV infection, pDC may be chronically activated rather than hypofunctional, and production of type I IFN chronically induced rather than inhibited. The hypothesis that chronic pDC activation and type I IFN production may play a pivotal role in driving the immune dysfunction observed during HIV infection has brought alternative therapeutic methods to the attention of scientists and clinicians. The possibility that approaches aimed at blocking type I IFN or their signaling pathways may provide an immunologic benefit during HIV infection is supported by animal models showing that the prolonged stimulation of pDC causes dysfunctions similar to those observed in HIV-infected patients [46,47]. The expression of markers of chronic T-cell activation, considered a hallmark of HIV disease progression, may be at least, in part, dependent on HIV-induced type I IFN [48,49], and pDC from SIV natural hosts, which do not develop immunodeficiency and do not show signs of chronic immune activation, produce far less IFN-α/β in response to TLR-7 and -9 stimulation compared with human or macaque pDC [50]. Furthermore, recent evidence from a nonhuman primate study shows that early accumulation of pDC at the initial site of infection in the vaginal mucosa drives the affluence of CCR5+ CD4 T cells, which are targets for SIV infection at this site, ultimately favoring the systemic diffusion of the virus [51].

Activation of the type I IFN pathway by HIV can occur also through alternative pathways, directly involving gp120 signaling to monocytes/macrophages [52–54]. Furthermore, the extensive apoptosis of immune cells and necrotic damage at mucosal and lymphoid tissues during HIV infection may result in the induction of type I IFN by endogenous nucleic acids as described above [18,20,21]. Mobilization of microbial components from the disrupted gut mucosa may also contribute to activate the innate immune system, as suggested by the direct correlation observed between plasma levels of lipopolysaccharide and IFN-α in HIV-infected patients [55]. Although lipopolysaccharide is not likely the direct inducer of type I IFN, its translocation from the intestinal mucosa to the circulation may correlate with the presence of other molecules of viral or bacterial origin capable of inducing IFN-α/β [55].

Thus, the classic idea of type I IFN-based therapy as an antiviral approach against HIV replication, similar to what has been successfully done for other viral infections, is being reconsidered in favor of the exact opposite approach, aimed at inhibiting the overactivated immune mechanism that may have deleterious long-term consequences for the host. It is likely that, in vivo, type I IFN have both antiviral and pathogenic consequences at the same time; the key question that still needs to be answered is whether one effect prevails over the other or whether their relative contribution changes in different stages of the disease, and therefore which therapeutic approach is preferable. Preclinical studies and clinical trials following one or the other hypothesis are ongoing. A schematic representation of the pathway of HIV-mediated pDC activation and its potential antiviral and pathogenic consequences is shown in Figure 1. Table 1 shows a list of approved or prospective drugs which act on the type I IFN pathway and are or may be considered for the treatment of HIV infection.

HIV therapy: type I IFN as antiviral drugs

The well described antiviral activity of type I IFN posed the basis for them to be considered as therapeutic agents against HIV infection. In later years, the more profound understanding of the mechanisms underlying their induction and production have added new possibilities for therapeutic approaches aimed at mimicking or triggering these natural antiviral molecules.

■ Recombinant, pegylated & natural IFN-α

Type I IFN-based therapy relies on recombinant technology to produce recombinant IFN-α2a, IFN-α2b and, more recently, their pegylated forms, which have longer a half-life in vivo [56]. Natural IFN-α, purified from appropriately stimulated human leukocytes, is also approved for therapy, and has the advantage of containing all IFN-α subtypes, which also preserve their glycosylated structure [57]. Recombinant
IFN-β is also available, but it is regularly used for the treatment of multiple sclerosis rather than for viral infections [58]. Administration of IFN-α, in its recombinant, pegylated or natural form, is probably the most direct attempt to take advantage of the antiviral activity of these molecules. No significant differences have been reported between recombinant and natural IFN-α. Recombinant IFN-β1b has rarely been considered as an antiviral agent [201].
The use of IFN-α to treat HIV-infected patients has been considered and tested since the first half of the 1980s [59]. Most clinical trials have focused on co-infection with HIV and other viral opportunistic pathogens such as Kaposi’s sarcoma virus, HCV and HBV. A beneficial effect of IFN-α was immediately recognized in the treatment of Kaposi’s sarcoma in HIV patients in whom the number of circulating CD4 T cells was at least partially preserved [60]. By the early 1990s several independent studies indicated IFN-α as an efficient anti-tumor drug in HIV patients with Kaposi’s sarcoma who had CD4 counts higher than 200 cells/mm³ (reviewed in [61]). The anti-tumor effect was often associated with a reduction in the circulating levels of HIV p24 antigen (determination of plasma viral RNA by PCR was not yet available), suggesting a partial anti-HIV effect [61]. IFN-α has also been successfully used in the treatment of viral hepatitis, associated or not with HIV infection, and pegylated IFN-α is still an integral part of the treatment of choice for HBV and HCV (reviewed in [62,63]). Despite this early interest in type I IFN as a therapeutic approach against HIV infection, the fact that their efficacy was limited to immunocompetent patients together with the introduction of azidothymidine first and then HAART have reduced the enthusiasm and dampened the interest for this approach. Of the registered clinical trials on type I IFN therapy for the purpose of treating primarily HIV rather than other opportunistic infections, only four are still active and only two of these are still actively recruiting [202,203]. A recent study on chronically SIV-infected macaques showed that short-term treatment (daily dose for 14 weeks) with pegylated IFN-α2a had no effect on plasma viremia, despite inducing transient increases in the expression of type I IFN-inducible genes [64]. Yet, recent studies on co-infection with GB virus C in HIV-infected patients receiving HAART have shown that the activation of genes associated with the type I IFN pathway correlated with the better prognosis normally observed in these patients [65,66]. These studies suggest that stimulation of the type I IFN system may be beneficial when HIV replication,

| Active compound | Target | Mechanism of action | Clinical application |
|-----------------|--------|---------------------|---------------------|
| **Agonists**    |        |                     |                     |
| CpG ODN         | TLR-9  | Type I IFN induction (therapeutic agent or vaccine adjuvant) | Colorectal and esophageal cancer* | Pneumococcus (HIV-associated)* |
|                 |        |                     | Mycosis Fungoides* | Non-Hodgkin Lymphoma* |
|                 |        |                     | HBV, HCV*         |                     |
| Imiquimod and resiquimod | TLR-7 | Type I IFN induction | Skin cancers | Genital warts |
|                 |        |                     | Other skin conditions |                     |
| Natural IFN-α, Recombinant and pegylated IFN-α2a/2b | IFNAR | IFNAR engagement and signaling | HCV, HBV, KSHV | Malignancies (several) |
| Recombinant IFN-β1b | IFNAR | IFNAR engagement and signaling | Multiple sclerosis | Cardiomyopathies* |
| **Antagonists** |        |                     | KSHV, CMV (HIV-associated)* |                     |
| Soluble CD4 Ig^† | CD4   | HIV–CD4 interaction blockade | Malaria | Rheumatoid arthritis |
| Anti-gp120^‡   | Gp120  | HIV–CD4 interaction blockade | Systemic lupus erythematosus | Glioblastoma* |
| Chloroquine     | Endosome | Prevention of endosomal acidification | Metabolic Syndrome X* | Chikungunya fever* |
| Anti-IFN-α mAb  | IFN-α  | IFNAR–IFN-α interaction blockade | Systemic lupus erythematosus* | Psoriasis* |
|                 |        |                     | Dermatomyositis or Polymyositis* |                     |

*Clinical trials ongoing for these conditions.
^†Tested for inhibition of HIV replication, not as immunomodulators.
CMV: Cytomegalovirus; IFN: Interferon; IFNAR: Type I interferon receptor; KSHV: Kaposi’s sarcoma-associated herpesvirus; mAb: Monoclonal antibody; ODN: Oligodeoxynucleotides; TLR: Toll-like receptor.
the principal chronic stimulus for pDC activation, is efficiently suppressed by HAART. In addition, a recent study involving HCV/HIV-co-infected patients showed that administration of pegylated IFN shortly after HAART interruption delayed the rebound of HIV plasma viral load [67].

TLR-7 & TLR-9 agonists

Different steps of the pathway of pDC activation and type I IFN signaling could be considered as a potential target for inducing or enhancing an antiviral response (Figure 1). However, as of today, only agonists of IFNAR, in the form of recombinant or natural IFN-α and IFN-β, are regularly used as therapeutic agents, even when conditions other than HIV infection are considered. The direct stimulation of pDC through TLR agonists, particularly targeting TLR-9 and -7, may provide an alternative to the use of recombinant or natural type I IFN. The potential for the use of TLR-7 and -9 agonists in different clinical indications has been recently reviewed elsewhere [68]. This review will focus specifically on their potential and their limitations as therapeutic agents in HIV infection. CpG oligodeoxynucleotides (ODNs) are potent agonists of TLR-9 and induce type I IFN production both in vitro and in vivo [69]. The clinical applications for which CpG ODNs are currently being considered involve primarily their use as adjuvants in vaccination strategies, taking advantage of their ability to boost the innate immune response, which in turns favors the development of efficient vaccine-induced adaptive immunity [68]. TLR-7 agonists, such as imiquimod and resiquimod, are commonly used in topically applied cream formulations for the treatment of skin conditions such as virus-induced genital warts [70,71]. However, preparations of both imiquimod and resiquimod for oral administration have been developed and have undergone clinical trials for chronic infections [72].

In the case of HIV infection, CpG ODNs could be considered not only as adjuvants in vaccine-based therapy or prophylaxis, but also as therapeutic agents taking advantage of the antiviral activity of type I IFN. In vivo, CpG ODNs were shown to improve vaccine-induced memory T-cell responses, and their application as adjuvants to improve vaccine-induced T-cell responses represents one of their main prospective clinical applications in the setting of HIV infection [73]. Although of interest, these applications inevitably rely on the delivery of an efficient vaccine, which is still not available for HIV. Whether sub-optimal vaccine strategies that have already been investigated can be significantly improved by optimizing the adjuvant with which they are paired remains to be determined. A therapeutic approach can be considered based on the potential type I IFN-mediated anti-HIV activity of CpG ODN, as demonstrated for thymic pDC in vitro [74]. CpG ODN were also shown to improve the anti-HIV activity of other effector cells of the innate arm of the immune response. For example, the lysis of infected CD4 T cells by natural killer cells is dependent on type I IFN production by pDC, and is therefore positively affected by CpG ODNs in vitro [75]. A similar application has been proposed for the TLR-7 agonist imiquimod, which was tested in a Phase I study for administration to asymptomatic HIV-infected patients, but did not result in a consistent reduction in viral load, despite increasing circulating levels of type I IFN in all treated patients [76]. The question can be raised as to which advantages and disadvantages the administration of TLR-7 and -9 agonists may have compared with IFN-α/β. Although the proposed therapeutic ability of molecules that stimulate pDC depends largely on the induction of type I IFN production, this approach may have a broader biological effect than the simple use of recombinant or natural IFN-α. Thus, by stimulating pDC, TLR-7 and -9 agonists may promote not only the production of type I IFN, but also the maturation of pDC into effector cells with cytotoxic, antigen presenting and migratory ability [36]. In particular, the expression of the chemokine receptor CCR7 on activated pDC may contribute to their migration to lymph nodes [77], which are important reservoirs for HIV [78]. Although many of the phenotypic and functional changes induced by TLR-7 and -9 agonists in pDC depend themselves on type I IFN signaling, direct stimulation of pDC via TLR-7 or -9 may still provide an anatomic advantage over the simple administration of IFN-α, in that activated pDC will produce antiviral type I IFN directly in the sites where HIV is actively replicating, whereas the dynamics with which IFN-α distributes in lymphoid tissue is hard to predict. On the other hand, chronic HIV infection results in progressive impairment of pDC responsiveness to TLR-7 and -9 stimulation [41], which may undermine the potential efficacy of treatments which target these receptors. This hyporesponsiveness is in part caused by viral proteins, such as gp120-mediated inhibition of TLR-9 activation [79], and in part by the fact that HIV itself is a powerful and persistent stimulus for pDC, causing them to be refractory to further stimulation due to...
Type I interferon in HIV treatment | REVIEW

HIV therapy: type I IFN as therapeutic targets

Ideally, the optimal therapy against a viral infection is the one aimed at clearing the organism of the infectious agent or, at least, reducing the replication and spread of the virus. In this respect, the approaches described so far, based on the antiviral activity of type I IFN, are the most obvious way of taking advantage of these molecules. However, HIV may represent an exception compared with other viruses, in that the disease associated with the infection is characterized by a progressive exhaustion of the immune system, as a consequence of its chronic hyperstimulation. Furthermore, the antiproliferative and proapoptotic effects of type I IFN on T lymphocytes and other immune cells, support the hypothesis that chronic activation of pDC and of the type I IFN system may be an important contributor to the immunodeficiency caused by HIV.

- Re-evaluation of the role of type I IFN in HIV infection

Although the mechanisms through which HIV causes progressive impairment of immune function are still not fully elucidated, it is well accepted that the lymphotropic nature of HIV and its ability to chronically trigger immune responses eventually results in the exhaustion of the immune system. pDC and type I IFN may play a pivotal role in this process, and their activation by HIV may be favored by the binding of gp120 to CD4. Furthermore, HIV differs from most chronic viral infections in that it preferentially replicates in lymphoid tissues and produces cell-free virions throughout the course of infection, therefore providing a constant and systemic stimulus for pDC (reviewed in [82]). Chronic overproduction of type I IFN has been suggested to contribute to:

- Selective ligand/receptor-mediated CD4 T-cell apoptosis (reviewed in [83]);
- Suppression of T-cell responses via inhibitory ligands [49];
- Induction of T-cell activation markers [48];
- Generalized lymphadenopathy, similar to what is observed in murine models [46,47].

Furthermore, a recent study showed that natural hosts of SIV, such as sooty mangabeys, are characterized by reduced type I IFN production by pDC in response to TLR-7 and -9 engagement compared with rhesus macaques [50]. This difference correlates with the absence of AIDS in SIV natural hosts [50], suggesting that in disease-susceptible hosts the chronic activation of pDC and subsequent type I IFN production may play a major role in the exhaustion of the immune system [22]. Concomitantly, the role of type I IFN in raising and sustaining both T-cell and B-cell responses [84–87] may directly favor the chronic hyperactivation of adaptive immune responses, repeatedly reported as a main contributor to HIV pathogenesis [81,88–90]. Moreover, a topical anti-inflammatory agent, which prevented pDC accumulation in the vaginal mucosa, protected rhesus macaques from SIV infection through the vaginal route [51], underscoring the important role that pDC have in also favoring the recruitment of activated T cells at the site of infection, thus fueling the initial burst of viral replication [51].

Taken together, these observations posed the rationale for changing the therapeutic approach to HIV infection with regards to the type I IFN system. Thus, different interventions are currently under investigation with the goal of counteracting or suppressing the deleterious consequences of HIV-induced pDC activation on the immune system [22].

- Blockers of IFN-α/IFNAR interaction

The biologic effects of type I IFN are mediated through the engagement of their specific receptor on target cells. In vitro, blocking antibodies against IFN-α or IFNAR prevent most of the negative effects of HIV-induced pDC activation, including T-lymphocyte apoptosis [44], immunosuppression and expression of activation markers [48,49]. In mouse models, the deleterious consequences of repeated administration of TLR-7 and -9 are limited or absent in IFNAR knockout mice [46,47], confirming the pivotal role of IFNAR engagement by type I IFN in the pathogenic effect of chronic pDC stimulation. Hence, the
possibility of utilizing blocking antibodies against type I IFN or their receptor IFNAR is a relatively simple and straightforward therapeutic approach.

Antibodies which act as antagonists of IFNAR have been widely used in vitro [36,48,49], but their development into therapeutic agents has not yet reached the phase of human clinical trials. On the contrary, fully humanized monoclonal antibodies against IFN-α (MEDI-545, Medimmune, Gaithersburg, MD, USA) are under clinical experimentation for use in the treatment of autoimmune conditions such as systemic lupus erythematosus (SLE). Two Phase I trials have been completed (SLE and chronic plaque psoriasis [204,205]); two Phase I trials (SLE and dermatomyositis or polymyositis [206,207]) and one Phase II trial (SLE [208]) are currently recruiting.

The result of trials on anti-IFN-α antibodies to SLE may be particularly informative with regard to their potential application in HIV infection. Thus, SLE and HIV disease share not only the over activation of the pDC/type I IFN system [22,91], but also some of their most defining immune abnormalities (reviewed in [92]), such as:

- Decreased CD4 T-cell count
- Expression of T-cell activation markers
- Impaired T-cell responses to antigens and mitogens
- B-cell dysfunction
- Imbalance of type 1 and type 2 cytokines
- Increased risk of opportunistic infections

If an improvement of these conditions can be induced in SLE patients by anti-IFN-α antibodies treatment, the possibility of a positive impact on HIV infection using the same or similar approaches may be concrete.

One of the disadvantages that blockade of type I IFN or IFNAR may have is the lack of specificity of the approach, in that ablation of type I IFN signaling, if achieved, may negatively affect the balance of the immune response by disturbing the physiologic immunoregulatory function of type I IFN besides relieving their pathogenic pressure. Also, the ablation of type I IFN responses may impair the efficient immune response to other infections, for which a functional IFN-α/β system is a vital requirement.

A different approach aimed at countering the overproduction of IFN-α was attempted in the mid–late 1990s with encouraging results [93,94]. HIV-infected patients were immunized against IFN-α2b in order to induce the production of neutralizing antibodies which would prevent type I IFN signaling. The immunization was efficacious in the Phase I/II studies, and immunized patients showed better preservation of CD4 count and delayed clinical deterioration [93]. In the Phase II/III study that followed, a suboptimal immunization protocol (three oil-adjuvanted injections were used in the Phase II/III trial, compared with six or seven in the Phase I/II study) was used, and production of neutralizing antibodies was induced only in one-third of the enrolled patients [94]. However, patients who responded to immunization with an increase in anti-IFN-α antibodies showed a lower rate of disease progression [94]. Owing to the introduction of protease inhibitors in HIV therapy during the period of the trial, more than 60% of the patients enrolled were elected to add these drugs to their regimen, and experienced the marked improvements in clinical progression normally observed with HAART [94]. This change in therapy made it impossible to achieve the expected end points of the study, prompting to halt further follow-up studies [94]. Nevertheless, these studies suggest that interventions aimed at interfering with type I IFN signaling may prove beneficial in the treatment of HIV disease.

Alternative approaches to interfere with the type I IFN system may target the mechanism through which HIV activates pDC. The characterization of pDC as major producers of type I IFN and the dissection of their activation pathway have highlighted a number of potential molecular targets for inhibiting HIV-mediated pDC activation. Prospective therapeutic agents directed against the pDC activation pathway are presented below.

- **TLR-7 & TLR-9 antagonists**

  pDC sense HIV through intracellular TLR-7 and -9, which have evolved to recognize viral nucleic acids [35]. Nonstimulatory DNA sequences have been identified that can antagonize the stimulatory effect of both TLR-7 and -9 ligands [95,96]. In particular, immunoregulatory sequences (Dynavax Technologies, Berkley, CA, USA) have been shown to block pDC activation by both DNA and RNA viruses, including HIV [50,95]. Similar to anti-IFN-α antibodies, these TLR-7 and -9 antagonists are now being considered for the treatment of SLE [68], and upcoming clinical trials may provide important information on their applicability to HIV infection. However, immunoregulatory sequences also share the same risks highlighted for anti-IFN-α antibodies, in
that their prolonged administration, which may be required for chronic conditions such as HIV, may have unpredictable effects on the regulatory balance of the immune system and potentially favor other opportunistic viral infections by impeding innate immune responses.

**Chloroquine & hydroxychloroquine**

The increasing interest in molecules that may interfere with HIV-associated chronic immune activation has attracted the attention of scientists and clinicians towards chloroquine and hydroxychloroquine, two compounds which have been largely used for the treatment of malaria, and that affect the acidification of endosomes in phagocytic cells [97]. Chloroquine and hydroxychloroquine diffuse through the cell membrane and raise the pH of endocytotic vesicles [97]. Besides being necessary for the life cycle of *Plasmodium* (hence the antimalaric activity of chloroquine and hydroxychloroquine), the acidic pH is also required for processing engulfed pathogen and presenting their antigens [98], as well as exposing nucleic acids to TLR-7 and -9 in pDC [99]. The activation of pDC by HIV, and its consequences on the phenotype and function of T cells, are also sensitive to inhibition by chloroquine [35,36,48–50]. Because it is already approved for use in the treatment of malaria and autoimmune disorders such as SLE and rheumatoid arthritis, chloroquine is probably the drug with the most immediate potential for application to HIV treatment. A Phase II/III trial [109] is already recruiting for testing the antiviral and anti-inflammatory effect of chloroquine in HIV-infected patients. Chloroquine presents the additional advantage of having demonstrated an inhibitory effect on HIV replication *in vitro* [100]. Thus, chloroquine may have a beneficial effect on HIV disease by two separate routes: an effect on HIV replication with consequent reduction of the chronic immune-activating viral stimulus, and a direct effect on pDC activation, reducing their responsiveness to HIV and therefore limiting chronic immune activation. Besides the same downsides noted above for other immunoregulatory agents such as TLR-7 and -9 antagonists and anti-IFN-α antibodies, the prospect of long-term administration of chloroquine or hydroxychloroquine must take into consideration the well known adverse effects reported for these drugs, some of which are potentially serious such as severe damage to vision, which can occur with chronic use [101].

Both chloroquine and TLR antagonists have the disadvantage that they would be inefficient in preventing type I IFN production resulting from triggering of retinoic acid-inducible gene-I-like receptors in infected cells [18], gp120 interaction with monocytes/macrophages [52–54] and endogenous nucleic acids resulting from apoptotic or necrotic events [18,20]. The latter mechanism, in particular, has been hypothesized to play a role in the pathogenesis of certain autoimmune disorders, and may also contribute to HIV pathogenesis [18,20].

**Soluble CD4-Ig & anti-gp120**

Production of type I IFN by pDC is part of the normal early innate immune response against viral infections [17,102]. However, during HIV infection, pDC stimulation continues throughout the course of the disease [22,39]. Furthermore, HIV possesses a characteristic feature that distinguishes it from most viruses, in that it engages the target cells via CD4. Blockade of gp120–CD4 interactions inhibits the induction of type I IFN and other pDC-mediated immunoregulatory mechanisms *in vitro* [35,36,103,104]. This interaction can be antagonized in at least two different ways: by using antibodies directed against the HIV envelope protein gp120; or by using a recombinant soluble form of human CD4 (sCD4-Ig) [104]. Both these molecules were tested in the early 1990s for their potential as anti-HIV drugs (Table 1), with particular interest toward sCD4-Ig [105]. However, the limited effect on viral replication (measured as p24 antigen, as HIV RNA measurement by PCR was not yet available) and the almost complete lack of effect on CD4 count [105], rapidly dissipated the enthusiasm over the therapeutic potential of these molecules. Furthermore, the availability of more efficient antiretroviral drugs during the period in which sCD4-Ig was tested, shifted the interest of scientists and clinicians toward more efficient approaches. Nevertheless, extensive studies on the potential of sCD4-Ig as a modulator of the immunologic effects of HIV, rather than viral replication, have never been performed. Thus, such an approach may not have a strong impact on the plasma virus levels, but may prevent or counteract the chronic activation of type I IFN, with important positive consequences on other markers of disease progression, such as T-cell activation and immune function.
The use of specific blockers of HIV–pDC interaction also presents the advantage of not interfering, as far as it can be predicted, with the physiologic function of pDC and type I IFN. Thus, despite being very efficient in inhibiting pDC activation by HIV, there is no reason to believe that sCD4-Ig may affect the ability of pDC to recognize and produce type I IFN in response to other viruses, leaving the capacity of these cells to initiate an early innate immune response against other opportunist infections intact. In light of these observations, an approach aimed at specifically blocking the initial interaction of HIV with pDC, using sCD4-Ig or other similar molecules, may be the best therapeutic option to interfere with the type I IFN system. Furthermore, directly inhibiting HIV-mediated pDC activation may affect other pathogenic mechanisms that are not strictly dependent on type I IFN signaling, but require pDC activity. Thus, the expression of the immunosuppressive enzyme indoleamine 2,3-dioxygenase is induced in pDC upon exposure to HIV [48,103], and activation of this mechanism may in turn drive the differentiation of regulatory T cells [106], potentially contributing to the generalized impairment of T-cell responses [107,108].

Conclusions & future perspective
Type I IFN have long been known as potent natural antiviral agents, and therefore considered as potential therapeutic agents to counteract the progression and spread of different viral infections, including HIV. However, the advances made in understanding HIV pathogenesis have forced a re-evaluation of the role that type I IFN may have in this disease, underscoring how their chronic production may have deleterious effects on the immune system. This alternative view nourished the interest for therapeutic agents that inhibit type I IFN production or signaling, with the goal of limiting the immunologic damage that they may cause during HIV infection. It is likely that a balance exists between the beneficial antiviral effect and the deleterious consequences of type I IFN, and that the same balance extends to all prospective treatments that affect the pDC/type I IFN system.

New molecules that modulate pDC responses or type I IFN function are being considered alongside long-known drugs, such as chloroquine, which affect the same pathway. Although blocking the initial interaction of HIV with pDC, for example using sCD4-Ig, may be the best possible approach, the drug which currently appears to be closest to being used for the

Executive summary

**Type I interferon responses to HIV**
- Type I interferons (IFNs) exert powerful anti-HIV activity.
- HIV is a strong inducer of type I IFN production by plasmacytoid dendritic cells (pDC).
- pDC are overactivated in HIV-infected patients, which may contribute to the chronic activation and exhaustion of the immune system via type I IFN.

**HIV therapy: type I IFN as antiviral drugs**
- Recombinant, pegylated or natural IFN-α are used as antivirals against hepatitis and Kaposi’s sarcoma viruses, even when associated with HIV infection, but have been shown to have only limited effect on HIV disease itself.
- Toll-like receptor (TLR)-9 agonists are under trial as adjuvants and TLR-7 agonists are used in the treatment of virus-induced genital warts; both can be considered for HIV therapy as inducers of antiviral type I IFN.

**HIV therapy: type I IFN as therapeutic targets**
- Recent evidence suggests that overactivation of pDC and type I IFN production may contribute significantly to HIV pathogenesis and disease progression.
- Antibodies against IFN-α are under clinical trials for the treatment of systemic lupus erythematosus, and may be considered for blocking IFN-α signaling in HIV-infected patients to limit the damage caused by chronic type I IFN production.
- Antagonists of TLR-7 and -9 have been used in vitro to inhibit HIV-induced pDC activation and type I IFN production, but clinical trials have not yet started.
- Chloroquine and hydroxychloroquine are approved for the treatment of malaria and systemic lupus erythematosus, and may be used to inhibit HIV-induced pDC activation by blocking endosomal acidification. Clinical trials are ongoing.
- Soluble CD4-Ig was tested in the 1990s as a blocker of HIV infection, but may be reconsidered for its ability to prevent HIV-induced pDC activation.

**Conclusion**
- The view of scientists and clinicians on the role of type I IFN in HIV pathogenesis has changed: despite their potent antiviral activity, type I IFNs are now considered important contributors to HIV disease progression.
- The possibility of using recombinant type I IFN as anti-HIV drugs has been replaced by the idea of blocking type I IFN signaling or production to limit the damage they may cause to the immune system.
The purpose of inhibiting HIV-induced pDC activation is likely chloroquine. Encouraging results from the ongoing trials in which chloroquine is being tested for HIV infection may open the door not only for testing compounds which are already available, but also for seeking the development of novel therapeutic agents which target the same pathway, for example by inhibiting key molecular components of the TLR-7 and -9 or IFNAR signal transduction pathways.

**Financial & competing interests disclosure**

The author has no relevant affiliations or financial involvement with any organization or entity that may have financial interests in or financial conflict with the subject matter or materials discussed in the manuscript. This includes employment, consultancies, honoraria, stock ownership or options, expert testimony, grants or patents received or pending, or royalties.

No writing assistance was utilized in the production of this manuscript.

**Bibliography**

Papers of special note have been highlighted as:

* of interest
** of considerable interest

1. Isaacs A, Lindenmann J: Virus interference. I. The interferon. *Proc. R. Soc. Lond. B Biol. Sci.* 147, 258–267 (1957).
2. Pestka S: The interferons: 50 years after their discovery. *Science* 306, 1098–1102 (2004).
3. de Veer MJ, Holko M, Frevel M et al.: Functional classification of interferon-stimulated genes identified using microarrays. *J. Leukoc. Biol.* 69, 912–920 (2001).
4. Samuel CE: Antiviral actions of interferons. *Cytokine Growth Factor Rev.* 14, 778–809 (2001).
5. Silverman RH et al.: A scientific journey through the interferons. *Curr. Top. Microbiol. Immunol.* 311, 17–58 (2007).
6. Chan H, Bartos DP, Owen-Schaub LB: Activation-dependent transcriptional regulation of the human Fas promoter requires NF-κB p50-p65 heterodimeric activity. *J. Biol. Chem.* 272, 2098–2108 (1999).
7. Grandvaux N, tenOever BR, Servant MJ, Hiscott J: The interferon antiviral response: from viral invasion to evasion. *Curr. Opin. Infect. Dis.* 15, 259–267 (2002).
8. Kuhnel F, Zender L, Paul Y et al.: NF-κB mediates apoptosis through transcriptional activation of Fas (CD95) in adenoviral hepatitis. *J. Biol. Chem.* 275, 6421–6427 (2000).
9. Baetu TM, Kwon H, Sharma S, Grandvaux N, Hiscott J: Disruption of NF-κB signaling reveals a novel role for NF-κB in the regulation of TNF-related apoptosis-inducing ligand expression. *J. Immunol.* 167, 3164–3173 (2001).
10. Rivera-Walsh I, Waterfield M, Xiao G, Song A, Sun SC: NF-κB signaling pathway governs TRAIL gene expression and human T-cell leukemia virus-1 Tax-induced T-cell death. *J. Biol. Chem.* 276, 40585–40588 (2001).
11. Medzhitov R, Janeway CA Jr: Innate immune recognition and control of adaptive immune responses. *Semin. Immunol.* 10, 351–353 (1998).
12. Steinman RM, Hemmi H: Dendritic cells: translating innate to adaptive immunity. *Curr. Top. Microbiol. Immunol.* 311, 17–58 (2006).
13. Le Bon A, Tough DF: Type I interferon as a stimulus for cross-priming. *Cytokine Growth Factor Rev.* 19, 33–40 (2008).
14. Murphy KM, Ouyang W, Farrar JD et al.: Signaling and transcription in T helper development. *Annu. Rev. Immunol.* 18, 451–494 (2000).
15. Rogge L, Papi A, Presky DH et al.: Antibodies to the IL-12 receptor β2 chain mark human TH1 but not TH2 cells in vitro and in vivo. *J. Immunol.* 162, 3926–3932 (1999).
16. Creagh EM, O’Neill LA: TLRs, NLRs and RLRs: a trinity of pathogen sensors that co-operate in innate immunity. *Trends Immunol.* 27, 352–357 (2006).
17. Takeuchi O, Akira S: Recognition of viruses by innate immunity. *Immunol. Rev.* 220, 214–224 (2007).
18. Gilliet M, Cao W, Liu YJ: Plasmacytoid dendritic cells: sensing nucleic acids in viral infection and autoimmune diseases. *Nat. Rev. Immunol.* 8, 594–606 (2008).
19. Colonna M, Trinchieri G, Liu YJ: Plasmacytoid dendritic cells in immunity. *Nat. Immunol.* 5, 1219–1226 (2004).
20. Baccala R, Hobe K, Kono DH, Beutler B, Theofilopoulos AN: TLR-dependent and TLR-independent pathways of type I interferon induction in systemic autoimmunity. *Nat. Med.* 13, 543–551 (2007).
21. Conrad C, Meller S, Gilliet M: Plasmacytoid dendritic cells in the skin: to sense or not to sense nucleic acids. *Semin. Immunol.* (2009). (Epub ahead of print).
22. Boasso A, Shearer GM: Chronic innate immune activation as a cause of HIV-1 immunopathogenesis. *Clin. Immunol.* 126, 235–242 (2008).

* Proposes the mechanisms through which both T-cell impairment and phenotypic activation are driven by chronic activation of plasmacytoid dendritic cells.

23. Ho DD, Hartshorn KL, Rota TR et al.: Recombinant human interferon α-α suppresses HTLV-III replication in vitro. *Lancet* 1, 602–604 (1985).
24. Pitha PM: Multiple effects of interferon on the replication of human immunodeficiency virus type 1. *Antiviral. Res.* 24, 205–219 (1994).
25. Peng G, Lei KJ, Jin W, Greenwell-Wild T, Wahl SM: Induction of APOBEC3 family proteins, a defensive maneuver underlying interferon-induced anti-HIV-1 activity. *J. Exp. Med.* 203, 41–46 (2006).
26. Chiu YL, Greene WC: The APOBEC3 cytidine deaminases: an innate defensive network opposing exogenous retroviruses and endogenous retroelements. *Annu. Rev. Immunol.* 26, 317–353 (2008).
27. Rose KM, Martin M, Kozak SL, Kabat D: Transcriptional regulation of APOBEC3G, a cytidine deaminase that hypermutates human immunodeficiency virus. *J. Biol. Chem.* 279, 41744–41749 (2004).
28. Dolei A, Fattorossi A, D’Amelio R, Aiuti F, Dianzani F: Direct and cell-mediated effects of interferon-α and -γ on cells chronically infected with HTLV-III. *J. Interferon Res.* 6, 543–549 (1986).
29. Gendelman HE, Friedman RM, Joe S et al.: A selective defect of interferon-γ production in human immunodeficiency virus-infected monocyes. *J. Exp. Med.* 173, 277 (1991).
30. Kornbluth RS, Oh PS, Munis JR, Cleveland PH, Richman DD: Interferons and bacterial lipopolysaccharide protect macrophages from productive infection by human immunodeficiency virus in vitro. *J. Exp. Med.* 169, 1137–1151 (1989).
31 Jouvenet N, Neil SJ, Zhadina M et al.: Broad-spectrum inhibition of retroviral and filoviral particle release by tetherin. J. Virol. 83, 1837–1844 (2009).

32 Neil SJ, Zang T, Bieniasz PD: Tetherin inhibits retrovirus release and is antagonized by HIV-1 Vpu. Nature 451, 425–430 (2008).

33 Lapenta C, Santini SM, Proietti E et al.: Type I interferon in vivo HIV-1 infection and preserves human CD4+ T cells from virus-induced depletion in SCID mice transplanted with human cells. Virology 263, 78–88 (1999).

34 Hosmalin A, Lebon P: Type I interferon production in HIV-infected patients. J. Leukoc. Biol. 80, 984–993 (2006).

35 Beignon AS, McKenna K, Skoberne M et al.: Endocytosis of HIV-1 activates plasmacytoid dendritic cells via Toll-like receptor-viral RNA interactions. J. Clin. Invest. 115, 3265–3275 (2005).

36 Hardy AW, Graham DR, Shearer GM, Herbeuval JP: HIV turns plasmacytoid dendritic cells (pDC) into TRAIL-expressing killer pDC and down-regulates HIV coreceptors by Toll-like receptor 7-induced IFN-α. Proc. Natl Acad. Sci. USA 104, 17453–17458 (2007).

37 Killian MS, Fujimura SH, Hecht FM, Levy JA: Similar changes in plasmacytoid dendritic cell and CD4 T-cell counts during primary HIV-1 infection and treatment. AIDS 20, 1247–1252 (2006).

38 Sachdeva N, Asthana V, Brewer TH, Garcia D, Asthana D: Impaired restoration of plasmacytoid dendritic cells in HIV-1-infected patients with poor CD4 T-cell reconstitution is associated with decrease in capacity to produce IFN-α but not proinflammatory cytokines. J. Immunol. 181, 2887–2897 (2008).

39 Abel K, Alegria-Hartman MJ, Rothauesler K, Marthas M, Miller CJ: The relationship between simian immunodeficiency virus RNA levels and the mRNA levels of α/β interferons (IFN-α/β) and IFN-α/β-inducible Mx in lymphoid tissues of rhesus macaques during acute and chronic infection. J. Virol. 76, 8433–8445 (2002).

40 Giavedoni LD, Velasquillo MC, Parodi LM, Hubbard GB, Hodara VL: Cytokine expression, natural killer cell activation, and phenotypic changes in lymphoid cells from rhesus macaques during acute infection with pathogenic simian immunodeficiency virus. J. Virol. 74, 1648–1657 (2000).

41 Tilton JC, Manion MM, Luskin MR et al.: Human immunodeficiency virus viremia induces plasmacytoid dendritic cell activation in vivo and diminished α interferon production in vitro. J. Virol. 82, 3997–4006 (2008).

**Elegant study showing that negative feedback induced by chronic stimulation renders plasmacytoid dendritic cells from HIV-infected patients refractory to further stimulation.**

42 Malleret B, Maneglier B, Karlsson I et al.: Primary infection with simian immunodeficiency virus: plasmacytoid dendritic cell homing to lymph nodes, type IFN-1, and immune suppression. Blood 112(12), 4598–4608 (2008).

43 Herbeuval JP, Boasso A, Grivel JC et al.: TNF-related apoptosis-inducing ligand (TRAIL) in HIV-1-infected patients and its in vitro production by antigen-presenting cells. Blood 105, 2458–2464 (2005).

44 Herbeuval JP, Grivel JC, Boasso A et al.: CD4+ T-cell death induced by infectious and noninfectious HIV-1: role of type 1 interferon-dependent, TRAIL/DR5-mediated apoptosis. Blood 106, 3524–3531 (2005).

45 Herbeuval JP, Nilsson J, Boasso A et al.: Differential expression of IFN-α and TRAIL/DR5 in lymphoid tissue of progressor versus nonprogressor HIV-1-infected patients. Proc. Natl Acad. Sci. USA 103, 7000–7005 (2006).

46 Heikenwalder M, Polymenidou M, Junt T et al.: Lymphoid follicle destruction and immunosuppression after repeated CpG oligodeoxynucleotide administration. Nat. Med. 10, 187–192 (2004).

**Excellent study showing for the first time the deleterious effects of prolonged plasmacytoid dendritic cell stimulation in vivo.**

47 Baenziger S, Heikenwalder M, Johansen P et al.: Triggering TLR7 in mice induces immune activation and lymphoid system disruption, resembling HIV-mediated pathology. Blood 113(2), 377–388 (2009).

48 Boasso A, Hardy AW, Anderson SA, Dolan MJ, Shearer GM: HIV-induced type I interferon and tryptophan catabolism drive T-cell dysfunction despite phenotypic activation. PLoS ONE 3, e2961 (2008).

49 Boasso A, Hardy AW, Landay AL et al.: PDL-1 upregulation on monocytes and T cells by HIV via type I interferon: restricted expression of type I interferon receptor by CCR5-expressing leukocytes. Clin. Immunol. 129(1), 132–144 (2008).

50 Mandl JN, Barry AP, Vanderford TH et al.: Divergent TLR7 and TLR9 signaling and type I interferon production distinguish pathogenic and nonpathogenic AIDS virus infections. Nat. Med. 14, 1077–1087 (2008).

51 Li Q, Estes JD, Schlievert PM et al.: Glycerol monolaurate prevents mucosal SIV transmission. Nature (2009) (Epub ahead of print).

**Interesting study showing that plasmacytoid dendritic cell accumulation favors the recruitment of activated CD4+ T cells, which are targeted for infection by Simian immunodeficiency virus in the vaginal mucosa.**

52 Ankel H, Capobianchi MR, Castilletti C, Dianzani F: Interferon induction by HIV glycoprotein 120: role of the V3 loop. Virology 205, 34–43 (1994).

53 Capobianchi MR, Ameglio F, Cordiali Fei P et al.: Coordinate induction of interferon α and β by recombinant HIV-1 glycoprotein 120. AIDS Res. Hum. Retroviruses 9, 957–962 (1993).

54 Gessani S, Puddu P, Varano B et al.: Induction of β interferon by human immunodeficiency virus type 1 and its gp120 protein in human monocytes-macrophages: role of β interferon in restriction of virus replication. J. Virol. 68, 1983–1986 (1994).

55 Brenchley JM, Price DA, Schacker TW et al.: Microbial translocation is a cause of systemic immune activation in chronic HIV infection. Nat. Med. 12, 1365–1371 (2006).

56 Youngster S, Wang YS, Grace M, Bausch J, Bondens R, Wyss DF: Structure, biology, and therapeutic implications of pegylated interferon-α-2b. Curr. Pharm. Des. 8, 2139–2157 (2002).

57 Sarkar FH: Pharmacokinetic comparison of leukocyte and Escherichia coli-derived human interferon type α. Antiviral. Res. 2, 103–106 (1982).

58 Buttmann M, Rieckmann P: Interferon-β1b in multiple sclerosis. Expert Rev. Neurother. 7, 227–239 (2007).

59 Hirsch MS, Kaplan JC: Prospects of therapy for infections with human T-lymphotropic virus type III. Ann. Intern. Med. 103, 750–755 (1985).

60 Lane HC, Kovacs JA, Feinberg J et al.: Antiretroviral effects of interferon-α in AIDS-associated Kaposis sarcoma. Lancet 2, 1218–1222 (1988).

61 Lane HC: The role of α-interferon in patients with human immunodeficiency virus infection. Semin. Oncol. 18, 46–52 (1991).

62 Foster G, Mathurin P: Hepatitis C virus therapy to date. Antisiv. Ther. 13(Suppl. 1), 3–8 (2008).
Type I interferon in HIV treatment

Kumar M, Sarin SK: Systematic review: combination therapies for treatment-naïve chronic hepatitis B. *Aliment Pharmacol Ther*. 27, 1187–1209 (2008).

Asmuth DM, Abel K, George MD, Dandekar S, Pollard RB, Miller CJ: Pegylated interferon-α 2a treatment of chronic SIV-infected macaques. *J. Med. Primatol.* 37, 26–30 (2008).

Capobianchi MR, Lalle E, Martini F et al.: Influence of GBV-C infection on the endogenous activation of the IFN system in HIV-1 co-infected patients. *Cell. Med. Biol.* 52, 3–8 (2006).

Dianzani F, Rozera G, Abbate I: Lalle E, Sacchi A, Abbate I et al.: Interferon may prevent HIV viral rebound after HAART interruption in HIV patients. *J. Interferon Cytokine Res.* 28, 1–3 (2008).

Guiducci C, Coffman RL, Barrat FJ: Signaling pathways leading to IFN-α production in human plasmacytoid dendritic cell and the possible use of agonists or antagonists of TLR7 and TLR9 in clinical indications. *J. Intern. Med.* 265, 43–57 (2009).

Jank M, Vollmer J: Therapeutic applications of synthetic CpG oligodeoxynucleotides as TLR9 agonists for immune modulation. *BioDrugs* 21, 387–401 (2007).

Hengge UR, Ruzicka T: Topical immunomodulation in dermatology: potential of Toll-like receptor agonists. *Dermatol. Surg.* 30, 1101–1112 (2004).

Navi D, Huntley A: Imiquimod 5 percent cream and the treatment of cutaneous malignancy. *Dermatol. Online J.* 10, 4 (2004).

Dockrell DH, Kinghorn GR: Imiquimod and resiquimod as novel immunomodulators. *J. Antimicrob. Chemother.* 48, 751–755 (2001).

Wille-Reece U, Flynn BJ, Lore K et al.: Toll-like receptor agonists influence the magnitude and quality of memory T-cell responses after prime-boost immunization in nonhuman primates. *J. Exp. Med.* 203, 1249–1258 (2006).

Gurney KB, Colanontio AD, Blom B, Spits H, Uittenbogaart CH: Endogenous IFN-α production by plasmacytoid dendritic cells exerts an antiviral effect on rhymic HIV-1 infection. *J. Immunol.* 173, 7269–7276 (2004).

Tomescu C, Chehimi J, Maino VC, Montaner LJ: NK cell lysis of HIV-1-infected autologous CD4 primary T cells: requirement for IFN-mediated NK activation by plasmacytoid dendritic cells. *J. Immunol.* 179, 2097–2104 (2007).

Goldstein D, Hertzog P, Tomkinson E et al.: Administration of imiquimod, an interferon inducer, in asymptomatic human immunodeficiency virus-infected persons to determine safety and biologic response modification. *J. Infect. Dis.* 178, 858–861 (1998).

Kim CH: The greater chemotactic network for lymphocyte trafficking: chemokines and beyond. *Curr. Opin Hematol.* 12, 298–304 (2005).

Shen L, Siliciano RF: Viral reservoirs, residual viremia, and the potential of highly active antiretroviral therapy to eradicate HIV infection. *J. Allergy Clin. Immunol.* 122, 22–28 (2008).

Martinelli E, Cicala C, Van Ryk D et al.: HIV-1 gp120 inhibits TLR9-mediated activation and IFN-α secretion in plasmacytoid dendritic cells. *Proc. Natl Acad. Sci. USA* 104, 3396–3401 (2007).

Douk, D: HIV disease progression: immune activation, microbes, and a leaky gut. *Top. HIV Med.* 15, 114–117 (2007).

Silvestri G, Paziardini M, Pandrea I, Lederman MM, Sodora DL: Understanding the benign nature of SIV infection in natural hosts. *J. Clin. Invest.* 117, 3148–3154 (2006).

Boasso A, Shearer GM, Chougnet C: Immune dysregulation in human immunodeficiency virus infection: know it, fix it, prevent it? *J. Intern. Med.* 265, 78–96 (2009).

Herbeuval JP, Shearer GM: HIV-1 immunopathogenesis: how good interferon turns bad. *Clin. Immunol. 123*, 121–128 (2007).

Havenaar-Daughton C, Kolumam GA, Murali-Krishna K: Cutting edge: the direct action of type I IFN on CD4 T cells is critical for sustaining clonal expansion in response to a viral but not a bacterial infection. *J. Immunol.* 176, 3315–3319 (2006).

Jego G, Palucka AK, Blanck JP, Chalouni C, Pascual V, Banchereau J: Plasmacytoid dendritic cells induce plasma cell differentiation through type I interferon and interleukin 6. *Immunity* 19, 225–234 (2003).

Kolumam GA, Thomas S, Thompson LJ, Sprent J, Murali-Krishna K: Type I interferons act directly on CD8 T cells to allow clonal expansion and memory formation in response to viral infection. *J. Exp. Med.* 202, 637–650 (2005).

Thompson LJ, Kolumam GA, Thomas S, Murali-Krishna K: Innate inflammatory signals induced by various pathogens differentially dictate the IFN-1 dependence of CD8 T cells for clonal expansion and memory formation. *J. Immunol.* 177, 1746–1754 (2006).

Giorgi JV, Hultin LE, McKeating JA et al.: Shorter survival in advanced human immunodeficiency virus type 1 infection is more closely associated with T-lymphocyte activation than with plasma virus burden or virus chemokine coreceptor usage. *J. Infect. Dis.* 179, 859–870 (1999).

Giorgi JV, Liu Z, Hultin LE, Cumberland WG, Hennessky K, Detels R: Elevated levels of CD38+ CD8+ T cells in HIV infection add to the prognostic value of low CD4+ T-cell levels: results of 6 years of follow-up. *The Los Angeles Center, Multicenter AIDS Cohort Study. J. Acquir. Immune Defic. Syndr.* 6, 904–912 (1993).

Liu Z, Cumberland WG, Hultin LE, Prince HE, Detels R, Giorgi JV: Elevated CD38 antigen expression on CD8+ T cells is a stronger marker for the risk of chronic HIV disease progression to AIDS and death in the Multicenter AIDS Cohort Study than CD4+ cell count, soluble immune activation markers, or combinations of HLA-DR and CD38 expression. *J. Acquir. Immune Defic. Syndr. Hum. Retrovir.* 16, 83–92 (1997).

Ronnhlo M, Pascual V: The innate immune system in SLE: type I interferons and dendritic cells. *Lupus* 17, 394–399 (2008).

Sekigawa I, Okada M, Ogasaawara H et al.: Lessons from similarities between SLE and HIV infection. *J. Infect.* 44, 67–72 (2002).

Gringeri A, Santagostino E, Cuasini M et al.: Absence of clinical, virological, and immunological signs of progression in HIV-1-infected patients receiving active anti-interferon-α immunization: a 30-month follow-up report. *J. Acquir. Immune Defic. Syndr. Hum. Retrovir.* 13, 55–67 (1996).

Gringeri A, Musico M, Hermans P et al.: Active anti-interferon-α immunization: a European–Israeli, randomized, double-blind, placebo-controlled clinical trial in 242 HIV-1-infected patients (the EURIS study). *J. Acquir. Immune Defic. Syndr. Hum. Retrovir.* 20, 358–370 (1999).

Barrat FJ, Meeker T, Gregorio J et al.: Nucleic acids of mammalian origin can act as endogenous ligands for Toll-like receptors and may promote systemic lupus erythematosus. *J. Exp. Med.* 202, 1131–1139 (2005).

Yamada H, Gursel I, Takeshita F et al.: Effect of suppressive DNA on CpG-induced immune activation. *J. Immunol.* 169, 5590–5594 (2002).

Fox RL, Kang HI: Mechanism of action of antimalarial drugs: inhibition of antigen processing and presentation. *Lupus* 2(Suppl. 1), S9–S12 (1993).
98 McCoy KL, Schwartz RH: The role of intracellular acidification in antigen processing. *Immunol. Rev.* 106, 129–147 (1988).

99 Lund JM, Alexopoulou L, Sato A et al.: Recognition of single-stranded RNA viruses by Toll-like receptor 7. *Proc. Natl Acad. Sci. USA* 101, 5598–5603 (2004).

100 Tsai WP, Nara PL, Kung HF, Oroszlan S: Inhibition of human immunodeficiency virus infectivity by chloroquine. *AIDS Res. Hum. Retroviruses* 6, 481–489 (1990).

101 Wozniacka A, McCauliffe DP: Optimal use of antimalarials in treating cutaneous lupus erythematosus. *Am. J. Clin. Dermatol.* 6, 1–11 (2005).

102 Ito T, Wang YH, Liu YJ: Plasmacytoid dendritic cell precursors/type I interferon-producing cells sense viral infection by Toll-like receptor (TLR) 7 and TLR9. *Springer Semin. Immunopathol.* 26, 221–229 (2005).

103 Boasso A, Herbeuval JP, Hardy AW et al.: HIV inhibits CD4+ T-cell proliferation by inducing indoleamine 2,3-dioxygenase in plasmacytoid dendritic cells. *Blood* 109, 3351–3359 (2007).

104 Herbeuval JP, Shearer GM: Are blockers of gp120/CD4 interaction effective inhibitors of HIV-1 immunopathogenesis? *AIDS Rev.* 8, 3–8 (2006).

105 Schacker T, Collier AC, Coombs R et al.: Phase I study of high-dose, intravenous rsCD4 in subjects with advanced HIV-1 infection. *J. Acquir. Immune Defic. Syndr. Hum. Retrovirol.* 9, 145–152 (1995).

106 Manches O, Munn D, Fallahi A et al.: HIV-activated human plasmacytoid DCs induce Tregs through an indoleamine 2,3-dioxygenase-dependent mechanism. *J. Clin. Invest.* 118, 3431–3439 (2008).

107 Boasso A, Shearer GM: How does indoleamine 2,3-dioxygenate contribute to HIV-mediated immune dysregulation. *Curr. Drug Metab.* 8, 217–223 (2007).

108 Boasso A, Vaccari M, Nilsson J et al.: Do regulatory T-cells play a role in AIDS pathogenesis? *AIDS Rev.* 8, 141–147 (2006).

### Websites

201 Phase III Randomized Double-Blind Placebo Controlled Study To Evaluate the Safety and Efficacy of Betaseron in AIDS and Advanced ARC Patients Receiving a Reduced-Dose AZT Regimen (NCT00002238). [http://clinicaltrials.gov/ct2/show/NCT00002238?term=NCT00002238&rank=1](http://clinicaltrials.gov/ct2/show/NCT00002238?term=NCT00002238&rank=1)

202 A Randomized, Dose-Ranging Study of Alferon LDO in Asymptomatic HIV Subjects (NCT00215852). [http://clinicaltrials.gov/ct2/show/NCT00215852?term=NCT00215852&rank=1](http://clinicaltrials.gov/ct2/show/NCT00215852?term=NCT00215852&rank=1)

203 Antiviral Activity of Peg-IFN-α-2A in Chronic HIV-1 Infection (NCT00594880). [http://clinicaltrials.gov/ct2/show/NCT00594880?term=NCT00594880&rank=1](http://clinicaltrials.gov/ct2/show/NCT00594880?term=NCT00594880&rank=1)

204 Safety and Tolerability of MEDI-545 in Patients Who Have Systemic Lupus Erythematosus (SLE) (NCT00482989). [http://clinicaltrials.gov/ct2/show/NCT00482989?term=NCT00482989&rank=1](http://clinicaltrials.gov/ct2/show/NCT00482989?term=NCT00482989&rank=1)

205 A Multicenter Study to Evaluate the Safety and Tolerability of Single-Dose for MEDI-545 (CP145) (NCT00472758). [http://clinicaltrials.gov/ct2/show/NCT00472758?term=NCT00472758&rank=1](http://clinicaltrials.gov/ct2/show/NCT00472758?term=NCT00472758&rank=1)

206 A Study to Evaluate the Safety and Tolerability of Multiple Intravenous Doses of MEDI 545 in Patients With Systemic Lupus Erythematosus (NCT00482989). [http://clinicaltrials.gov/ct2/show/NCT00482989?term=NCT00482989&rank=1](http://clinicaltrials.gov/ct2/show/NCT00482989?term=NCT00482989&rank=1)

207 A Study to Evaluate Safety of Multi-Dose MEDI-545 in Adult Patients With Dermatomyositis or Polymyositis (NCT00533091). [http://clinicaltrials.gov/ct2/show/NCT00533091?term=NCT00533091&rank=1](http://clinicaltrials.gov/ct2/show/NCT00533091?term=NCT00533091&rank=1)

208 A Study to Evaluate Safety and Tolerability of Subcutaneous Doses of MEDI-545 in Subjects With Lupus (NCT00657189). [http://clinicaltrials.gov/ct2/show/NCT00657189?term=NCT00657189&rank=1](http://clinicaltrials.gov/ct2/show/NCT00657189?term=NCT00657189&rank=1)

209 Investigating the Anti-Human Immunodeficiency Virus (HIV) & Anti-Inflammatory Effect of Chloroquine (NCT00308620). [http://clinicaltrials.gov/ct2/show/NCT00308620?term=NCT00308620](http://clinicaltrials.gov/ct2/show/NCT00308620?term=NCT00308620)